Enovis (NYSE:ENOV – Get Free Report) issued an update on its FY23 earnings guidance on Tuesday morning. The company provided EPS guidance of $2.22-2.36 for the period, compared to the consensus EPS estimate of $2.32.
Enovis Price Performance
ENOV opened at $53.59 on Friday. Enovis has a one year low of $43.88 and a one year high of $66.71. The business’s 50 day moving average price is $59.16 and its 200 day moving average price is $57.29. The company has a current ratio of 2.51, a quick ratio of 1.23 and a debt-to-equity ratio of 0.12.
Enovis (NYSE:ENOV – Get Free Report) last released its quarterly earnings data on Thursday, August 3rd. The company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.53 by $0.08. Enovis had a positive return on equity of 3.74% and a negative net margin of 8.52%. The firm had revenue of $428.50 million for the quarter, compared to analysts’ expectations of $420.06 million. During the same period in the prior year, the firm posted $0.59 earnings per share. The firm’s quarterly revenue was up 8.5% on a year-over-year basis. On average, research analysts forecast that Enovis will post 2.26 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Institutional Trading of Enovis
A number of large investors have recently modified their holdings of ENOV. Neuberger Berman Group LLC purchased a new stake in shares of Enovis during the first quarter worth $905,000. JPMorgan Chase & Co. purchased a new position in Enovis in the second quarter valued at $5,573,000. Bank of Montreal Can purchased a new position in Enovis in the second quarter valued at $532,000. UBS Group AG purchased a new position in Enovis in the second quarter valued at $1,211,000. Finally, FMR LLC purchased a new position in Enovis in the second quarter valued at $3,016,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufacture and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
- Five stocks we like better than Enovis
- How to Invest in Virtual Reality
- 2 Wrecked Stocks Keeping Cars on the Road Ready for Repair
- Which Wall Street Analysts are the Most Accurate?
- WeWork Stock Soars: Meme Stock Madness or Mirage?
- How and Why to Invest in Oil Stocks
- 3 Low-Cost ETFs That Are Crushing SPY
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.